These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32013055)

  • 1. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
    Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Ash S; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chi Fung Chan G; Ruud E; Schroeder H; Beck-Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32013055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
    Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
    Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
    Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
    J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
    Berlanga P; Pasqualini C; Pötschger U; Sangüesa C; Castellani MR; Cañete A; Luksch R; Elliot M; Schreier G; Kropf M; Morgenstern D; Papadakis V; Ash S; Ruud E; Brock P; Wieczorek A; Kogner P; Trahair T; Ambros P; Boterberg T; Castel V; Valteau-Couanet D; Ladenstein R
    Eur J Cancer; 2021 Feb; 144():1-8. PubMed ID: 33316634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
    Holmes K; Pötschger U; Pearson ADJ; Sarnacki S; Cecchetto G; Gomez-Chacon J; Squire R; Freud E; Bysiek A; Matthyssens LE; Metzelder M; Monclair T; Stenman J; Rygl M; Rasmussen L; Joseph JM; Irtan S; Avanzini S; Godzinski J; Björnland K; Elliott M; Luksch R; Castel V; Ash S; Balwierz W; Laureys G; Ruud E; Papadakis V; Malis J; Owens C; Schroeder H; Beck-Popovic M; Trahair T; Forjaz de Lacerda A; Ambros PF; Gaze MN; McHugh K; Valteau-Couanet D; Ladenstein RL;
    J Clin Oncol; 2020 Sep; 38(25):2902-2915. PubMed ID: 32639845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
    Garaventa A; Poetschger U; Valteau-Couanet D; Luksch R; Castel V; Elliott M; Ash S; Chan GCF; Laureys G; Beck-Popovic M; Vettenranta K; Balwierz W; Schroeder H; Owens C; Cesen M; Papadakis V; Trahair T; Schleiermacher G; Ambros P; Sorrentino S; Pearson ADJ; Ladenstein RL
    J Clin Oncol; 2021 Aug; 39(23):2552-2563. PubMed ID: 34152804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
    Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
    Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.
    Jain R; Trehan A; Menon P; Kapoor R; Kakkar N; Radhika S; Saxena AK; Mittal BR; Varma N; Samujh R; Bansal D
    Pediatr Hematol Oncol; 2021 May; 38(4):291-304. PubMed ID: 33622164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and Prognostic Impact of
    Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
    J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance.
    Barone G; Barry A; Bautista F; Brichard B; Defachelles AS; Herd F; Manzitti C; Reinhardt D; Rubio PM; Wieczorek A; van Noesel MM
    Paediatr Drugs; 2021 Nov; 23(6):537-548. PubMed ID: 34541620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
    Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
    Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.
    Wieczorek A; Manzitti C; Garaventa A; Gray J; Papadakis V; Valteau-Couanet D; Zachwieja K; Poetschger U; Pribill I; Fiedler S; Ladenstein R; Lode HN
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
    Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
    Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
    Ploessl C; Pan A; Maples KT; Lowe DK
    Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
    McGinty L; Kolesar J
    Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.
    Lucas JT; Wakefield DV; Doubrovin M; Li Y; Santiago T; Federico SM; Merchant TE; Davidoff AM; Krasin MJ; Shulkin BL; Santana VM; Lee Furman W
    Clin Transl Radiat Oncol; 2022 May; 34():42-50. PubMed ID: 35345864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia.
    Giljević JS; Rajačić N; Mikulić D; Batoš AT
    Children (Basel); 2022 Jun; 9(7):. PubMed ID: 35883927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.